NASDAQ:VOR 11 November 2025 - 9 December 2025

Vor Biopharma Inc. has exploded back onto traders’ screens. On December 9, 2025, the small-cap biotech surged roughly 31%, closing around $10.95 versus $8.36 the prior session, on volume tens of millions of shares—far above its recent daily average. StockAnalysis+1 The move followed new bullish coverage from JPMorgan, fresh clinical data around Vor’s lead drug telitacicept, and a controversial stock-option repricing that could shape the company’s governance story for years. GuruFocus+2Investing.com+2

Vor Biopharma Inc. priced an underwritten public offering of 10 million common shares at $10.00 per share for $100 million in expected gross proceeds. The company granted underwriters a 30‑day option to purchase up to 1.5 million additional shares. Vor expects the transaction to close on or about Wednesday, Nov. 12, 2025, subject to customary conditions. J.P. Morgan, Jefferies, Citigroup, and TD Cowen are joint book‑running managers. The deal is being made under a shelf registration declared effective on March 31, 2025; a final prospectus supplement will be filed with the SEC. GlobeNewswire+1 Investors reacted to the below‑market pricing with heavy pre‑market selling: